Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Glaucoma Market to Grow to $3.5 Billion by 2030
According to GlobalData, the glaucoma market across the seven major markets* is predicted to grow steadily from $2.8 billion in 2020 to $3.5 billion in 2030, with a compound annual growth rate (CAGR) of 2%. According to the latest analysis…
Oxular’s OXU-001 Receives IND Acceptence
The U.S. Food and Drug Administration has approved Oxular Limited’s investigational new drug application (IND) for suprachoroidal OXU-001 for the treatment of diabetic macular edema (DME). The IND permits the OXEYE Phase 2 trial to proceed, which will assess the…
Dacryoadenitis: Causes, Symptoms and Treatment
What Is Dacryoadenitis? Dacryoadenitis is an inflammatory condition that specifically targets the lacrimal glands, the glands responsible for tear production. Located in the upper outer region of each eye, these glands play an essential role in maintaining eye health by…
What Is Capsulorhexis and How It’s Done
What Is Capsulorhexis? Capsulorhexis, derived from the Latin “capsula” (little container) and Greek “rhexis” (rupture), refers to the precise and controlled tear of the anterior lens capsule during cataract surgery. This procedure creates a circular opening through which the cloudy…
All About Phacoemulsification Procedure | OBN
The phacoemulsification procedure has transformed cataract surgery, offering a less invasive and more efficient method for cataract removal. This advanced surgical technique uses ultrasonic vibrations to emulsify the cloudy lens, which is then aspirated out and replaced with an artificial…
GenSight Withdraws Application for Lumevoq in Europe
GenSight Biologics announced that it is withdrawing its application submitted to the European Medicines Agency (EMA) seeking approval for Lumevoq (lenadogene nolparvovec) in patients with Leber hereditary optic neuropathy (LHON). The decision comes after the Committee for Advanced Therapies (CAT)…
California Approves Expanded Scope of Practice Legislation
SACRAMENTO, Calif.—Two bills signed into law recently by Calif. Gov. Gavin Newsom will expand the scope of practice for optometrists in the state, according to a recent announcement by the California Optometric Association (COA). AB 407: Expanded Treatment for Non-Cancerous Anterior Segment…
Brim Biotech’s Clinical Trial for DED Kicks Off
BRIM Biotechnology has initiated the Phase 3 clinical trial of BRM421 for the treatment of Dry Eye Disease (DED) and enrolled the first patient in the trial. This multicenter, double-blind, randomized, vehicle-controlled trial will enroll over 700 patients with moderate…
The Biggest Challenges in Ophthalmology Today
A recent survey conducted by OBN on LinkedIn asked participants to identify the most pressing challenge facing the ophthalmology field today. The poll revealed that nearly half of the respondents believe patient access to care is the primary issue, followed…
New Consensus: Myopia Should Be Classified as a Disease
A new consensus report from the National Academies of Sciences, Engineering, and Medicine urges that myopia be classified as a disease requiring medical diagnosis. The report emphasizes the growing prevalence of myopia globally, which is projected to affect 5 billion…